Key Figures on **Biosimilars**

GBMA
Generic and Biosimilar Medicines Association

BIOSIMILARS IN EUROPE

15 YEARS

15 YEARS EUROPEAN EXPERIENCE

FIRST BIOSIMILAR
APPROVED IN EUROPE 2006

+2 billion
PATIENT DAYS

OVER 2 BILLION
PATIENT DAYS IN EUROPE[1]

BIOSIMILARS IN AUSTRALIA

FIRST BIOSIMILAR
IN AUSTRALIA IN 2010

INFLIXIMAB: FIRST BIOSIMILAR
MONOCLONAL ANTIBODY (mAb)
IN AUSTRALIA IN 2015

BIOSIMILAR INFLIXIMAB
44% PBS PRICE REDUCTION
SINCE 2015[2,3]

OUTCOMES



IMPROVED PATIENT ACCESS TO LIFE CHANGING MEDICINES
MORE PATIENTS TREATED FOR THE SAME COST

PBS SAVINGS THROUGH
COMPETITION AND PRICE DISCLOSURE

MORE $ AVAILABLE FOR THE PBS
TO SPEND ON NEW MEDICINES

1. Source: MIDAS MAT Q2 2020 data; rituximab and trastuzumab DDDs calculated via IQVIA Real World Data, Oncology Dynamics physician surveys on average cycles; pre-2009 analysis includes extrapolated treatment days for biosimilars launched between 2005 – 2008; country cohort includes 30 countries within Europe Economic Area
2. Gleeson D, et al. Financial costs associated with monopolies on biologic medicines in Australia. Australian Health Review. 2019;43:36-42. https://www.publish.csiro.au/ah/pdf/AH17031.
3. Australian Government. PBS Expenditure and Prescriptions Report 1 July 2018 to 30 June 2019. https://www.pbs.gov.au/statistics/expenditure-prescriptions/2018-2019/PBS_Expenditure_and_Prescriptions_Report_1-July-2018_to_30-June-2019.pdf. Accessed 5 November 2020.

Making medicines affordable